Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma Clinical Trial

Official title:

A Phase II Trial Evaluating the Efficacy of Polatuzumab Vedotin With Rituximab, Gemcitabine, Dexamethasone, and Cisplatin (PV-RGDP) Chemotherapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05498220
• Other study ID #: LCCC2033
• Status: Recruiting
• Phase: Phase 2
• Start date: February 17, 2023
• Est. completion date: August 2028

Study information

• Verified date: March 2024
• Source: UNC Lineberger Comprehensive Cancer Center
• Contact: Leah Randolph
• Phone: 919-966-4432
• Email: Leah_Randolph[@]med.unc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aimed to evaluate the efficacy of a novel regimen consisting of polatuzumab vedotin in combination with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP) for the treatment of diffuse large B-cell lymphoma that either came back or did not improve after the treatments (rrDLBCL).

This combination has not been approved by the Food and Drug Administration (FDA) for the treatment of rrDLBCL. Salvage therapy (treatment after standard treatment failed) needs to be improved. Rituximab, gemcitabine, dexamethasone, and cisplatin combination is a standard therapy for rrDLBCL and polatuzumab vedotin (PV) is a novel antibody-drug conjugate targeting CD79b. PV has shown efficacy in the setting of rrDLBCL and can improve the response rates of standard salvage therapy.

This study will focus on subjects in the first relapse (one prior regimen) and will include both subjects who are transplant eligible and those who are transplant ineligible.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 44
• Est. completion date: August 2028
• Est. primary completion date: August 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

In order to participate in this study, a subject must meet all of the eligibility criteria outlined below.

Inclusion Criteria:

1. Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.

2. Biopsy proven diffuse large B-cell lymphoma (DLBCL) in the first relapse (biopsy can be from initial diagnosis). The study will allow high-grade B cell lymphoma, but not including Burkitt's lymphoma.

3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.

4. Radiologic evidence of active disease within 28 days of starting trial therapy.

5. Only one prior line of therapy.

6. Prior cancer treatment must be completed at least 14 days prior to the start of treatment and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to = Grade 1 or start of treatment.

7. Subjects may be eligible or ineligible for autologous stem cell transplant

Exclusion Criteria:

1. Known severe, active bacterial, viral, fungal, mycobacterial, parasitic, or other infections at study enrollment that may put the subject at undue risk as determined by the investigator.

2. Subjective hearing loss interfering with daily activities or evidence of greater than mild hearing loss compared to age appropriate normal on screening audiometry are excluded.

3. Women who are pregnant or breastfeeding or who intend to become pregnant within a year of the last dose of study treatment.

4. Subjects with a history of prior or concurrent second primary malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the study drugs are eligible for enrollment in the trial.

5. Previous exposure to polatuzumab vedotin.

6. History of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine.

7. Contraindication to gemcitabine or cisplatin, or dexamethasone or similar corticosteroid.

8. Symptomatic cardiac disease including ventricular dysfunction, left ventricular ejection fraction < 40%, symptomatic coronary artery disease or symptomatic arrhythmias.

9. Must have a minimum level of pulmonary reserve defined as = Grade 1 dyspnea and pulse oxygenation > 91% on room air.

Related Conditions & MeSH terms

• Diffuse Large B-cell Lymphoma
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Large B-Cell, Diffuse

Intervention

Drug:
• Polatuzumab vedotin (PV)
1.8 mg/kg, intravenous, at day 1, in every 21 days
• Rituximab
375 mg/m2 intravenous, at day 1 or day 2, in every 21 days
• Hyaluronidase
1,400 mg/23,400 units sub-cutaneous, starts at cycle 2, in every 21 days
• Gemcitabine
1,000 mg/m2 intravenous at day 1 and 8, in every 21 days
• Cisplatin
75 mg/m2, intravenous, at day 1, in every 21 days
• Dexamethasone
40 mg intravenous at day 1, Per oral days at days 2-4
• GCSF
granulocyte-colony stimulating factor (GCSF )

Locations

Country	Name	City	State
United States	Lineberger Comprehensive Cancer Center	Chapel Hill	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
UNC Lineberger Comprehensive Cancer Center	Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall response rate (ORR)	ORR is defined as the proportion of subjects who received the study treatment, and achieved complete response (CR) or partial response (PR) by Lugano classification.; Complete Response: Complete metabolic response on Positron emission tomography (PET) image or Target nodes/nodal masses must regress to = 1.5 cm in the largest transverse diameter (LDi) or no extra lymphatic sites of disease on Computerized Tomography (CT).; Partial Response: Score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size on PET and =50% decrease in the sum of the products of diameters (SPD) of up to 6 target measurable nodes and extranodal sites on CT.	Up to 4 months (End of Treatment)
Secondary	Complete response rate (CR)	CR is defined as the proportion of subjects who received the study treatment, achieved complete response (CR) by the Lugano classification.	Up to 4 months (End of Treatment)
Secondary	Progression free survival (PFS)	PFS is defined as the time from the start of study treatment until progression by Lugano classification or death.; Progressive Disease: Score 4 or 5 with an increase in the intensity of uptake from baseline and/or new fluorodeoxyglucose (FDG) -avid foci consistent with lymphoma at the interim or end-of-treatment assessment on PET, or an individual node/lesion must be abnormal with LDi > 1.5 cm, increase by = 50% from the cross product of the shortest axis perpendicular to LDi (SDi) nadir and an increase in LDi or SDi from nadir: 0.5 cm for lesions = 2 cm, 1.0 cm for lesions > 2 cm.	Up to 2 years
Secondary	Overall Survival (OS)	OS is defined as the time from the start of treatment until death from any cause.	Up to 2 years
Secondary	Number of participants with adverse events	The number of participants with adverse events will be listed and tabulated by grade to determine the safety and toxicity.; Adverse Events will be graded according to The National Cancer Institute (NCI) of Common Terminology Criteria for Adverse Events (CTCAE) version 5. The scale is provided for each AE term. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.	Up to 2 years

External Links

•   University of North Carolina Lineberger Comprehensive Cancer Center Clinical Trials